| Literature DB >> 28408969 |
E Azzini1, E Venneria1, D Ciarapica1, M S Foddai1, F Intorre1, M Zaccaria1, F Maiani1, L Palomba1, L Barnaba1, C Tubili2, G Maiani1, A Polito1.
Abstract
The main objective of this research was to determine whether a commercial orange juice rich in anthocyanins could have an effect on body weight and on clinical parameters related to obesity including antioxidant status, lipid profile, and metabolic and inflammatory biomarkers. 11 women with an average BMI of 34.4 ± 4.8 kg/m2 were enrolled in a pilot study. Over a period of 12 weeks they received 500 mL daily dose into two doses (250 mL) of commercial red orange juice (COJ). The biochemical parameters were measured at baseline and at the end of the study (12 weeks). One month later upon free diet, a follow-up was performed measuring the same variables. The daily consumption of 500 mL of COJ had no significant effects on body weight, while there was a decrease in total cholesterol and LDL cholesterol. The grade of obesity implies different changes in inflammation biomarkers. In obese women, our data do not seem to support evidence that commercial red orange juice consumption acts as functional food preventing obesity and metabolic disorders such as insulin resistance and/or inflammatory status.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28408969 PMCID: PMC5376946 DOI: 10.1155/2017/1672567
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Commercial orange juice: nutritional values per 100 mL.
| Energetic value (kJ) | 188 |
|---|---|
| pH | 3.6 |
| Total soluble solids (°Brix) | 11.2 |
| Proteins (g) | 0.6 |
| Fats (g) | 0.1 |
| Carbohydrates (g) | 10.0 |
| Vitamin C (mg) | 55 |
| Anthocyanins (mg) | >50 |
Nutrients amount on data fixed by Ortogel.
Study design.
| Time → | ||||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 2 weeks | 4 weeks | 6 weeks | 8 weeks | 10 weeks | 12 weeks | Follow-up | |
| Medical examination | x | x | x | x | x | |||
| Anthropometric measurements | x | x | x | x | x | |||
| Blood withdrawn | x | x | x | |||||
| Lifestyle questionnaire | x | |||||||
| Food diary | x | x | x | x | x | x | x | x |
Changes in body composition following consumption of 500 mL of COJ.
| Before COJ | After COJ |
| Δa | |
|---|---|---|---|---|
| Body weight (kg) | 87.8 ± 4.5 | 88.9 ± 4.5 | n.s. | 0.4 (−2.7 to 3.96) |
| BMI (kg/m2) | 34.4 ± 1.4 | 34.6 ± 1.5 | n.s. | 0.2 (−1.2 to 1.7) |
| Waist circumference (cm) | 96.0 ± 2.9 | 96.0 ± 3.0 | n.s. | −0.0 (−5.6 to 6.3) |
| Hip circumference (cm) | 119.38 ± 3.0 | 119.06 ± 3.16 | n.s. | −0.3 (−4.2 to 3.0) |
| WHR | 0.807 ± 0.02 | 0.808 ± 0.02 | n.s. | 0.007 (−0.011 to 0.06) |
Data are expressed as mean ± SEM; n.s., not significant.
ANOVA: after COJ versus before COJ.
Δa: differences from after to before COJ (mean values and their 95% confidence intervals).
WHR: waist/hip circumferences.
Figure 1Mean changes in body weight over supplementation phase (12 weeks) and follow-up (one month later) by energy intake (mean ± SE).
Habitual energy, macronutrients, and micronutrient intake over supplementation phase (12 weeks) and one month later (follow-up).
| Before COJ | After COJ | Follow-up | |
|---|---|---|---|
| Energy (kJ/die) | 5623 ± 370 | 5704 ± 37 | 5489 ± 426 |
| Proteins (g/die) | 64 ± 4 | 55 ± 3 | 56 ± 2 |
| Lipids (g/die) | 58 ± 4 | 56 ± 8 | 54 ± 5 |
| PUFA (g/die) | 5.8 ± 1.6 | 5.2 ± 1.9 | 4.9 ± 1.0 |
| MUFA (g/die) | 8.7 ± 1.2 | 9.2 ± 2.0 | 8.5 ± 1.0 |
| SFA (g/die) | 14.7 ± 1.2 | 14.8 ± 1.7 | 12.8 ± 1.4 |
| Carbohydrates (g/die) | 145 ± 17 | 165 ± 11 | 154 ± 14 |
| Anthocyanins (mg/die) | 52 ± 8 | 41 ± 5 | 35 ± 6 |
| Ascorbic acid (mg/die) | 78 ± 17 | 62 ± 11 | 67 ± 8 |
| Fibra | 11.6 ± 1.3 | 11.0 ± 1.0 | 11.9 ± 0.4 |
| Iron (mg/die) | 6.75 ± 0.49 | 6.53 ± 1.47 | 6.82 ± 1.40 |
| Calcium (mg/die) | 406 ± 41 | 324 ± 50 | 422 ± 46 |
| Retinol eq. ( | 714 ± 101 | 686 ± 114 | 916 ± 201 |
|
| 8.51 ± 0.88 | 8.94 ± 1.15 | 9.12 ± 0.87 |
Data are expressed as mean ± SE.
No statistical difference between phases.
Biochemical and hemodynamic parameters over 12 weeks following COJ consumption and one month later on free diet (follow-up).
| Before COJ | After COJ |
| Δa | Follow up |
| |
|---|---|---|---|---|---|---|
| Systolic pressure (mmHg) | 125 ± 5 | 131 ± 5 | n.s. | 6 (−15 to 16) | 122 ± 4 | n.s. |
| Diastolic Pressure (mmHg) | 81 ± 2 | 83 ± 3 | n.s. | 3 (−10 to 10) | 74 ± 2 | 0.01 |
| FRAP ( | 832 ± 45 | 827 ± 42 | n.s. | −5 (−93 to 116) | 841 ± 61 | n.s. |
| Uric acid (mg/dL) | 4.6 ± 0.4 | 4.4 ± 0.4 | n.s. | −0.2 (−0.9 to 1.0) | 4.7 ± 0.4 | n.s. |
| Total cholesterol (mg/dL) | 170 ± 14 | 158 ± 13 | n.s. | −11 (−55 to 7) | 164 ± 14 | n.s. |
| Triglycerides (mg/dL) | 104 ± 21 | 106 ± 16 | n.s. | 3 (−108 to 89) | 123 ± 20 | n.s. |
| HDL-cholesterol (mg/dL) | 66 ± 3 | 63 ± 2 | n.s. | −3 (−15 to 4) | 65 ± 2 | n.s. |
| LDL-cholesterol (mg/dL) | 83 ± 12 | 74 ± 13 | 0.046 | −9 (−30 to 12) | 74 ± 13 | n.s. |
| Vitamin A ( | 52.1 ± 8.3 | 49.4 ± 7.5 | n.s. | −2.7 (−22.5 to 7.6) | 53.0 ± 8.0 | 0.04 |
| Vitamin E (mg/dL) | 1.32 ± 0.16 | 1.28 ± 0.16 | n.s. | 0.08 (−0.40 to 0.33) | 1.24 ± 0.16 | 0.007 |
| Vitamin C (mg/dL) | 1.01 ± 0.05 | 1.18 ± 0.08 | n.s. | 0.17 (−0.16 to 0.62) | 1.06 ± 0.09 | n.s. |
| AA (mg/dL) | 0.59 ± 0.07 | 0.64 ± 0.12 | n.s. | 0.06 (−0.42 to 0.69) | 0.52 ± 0.07 | n.s |
| DHA (mg/dL) | 0.42 ± 0.08 | 0.53 ± 0.07 | n.s. | 0.115 (−0.52 to 0.44) | 0.54 ± 0.07 | n.s |
Data are expressed as mean ± SEM; n.s., not significant.
AA: ascorbic acid; DHA: dehydroascorbic acid.
P: ANOVA.
Δa: differences from after to before COJ (mean values and their 95% confidence intervals).
Metabolic and inflammatory biomarkers over supplementation phase (12 weeks) and follow-up (one month later).
| Before COJ | After COJ |
| Δa | Follow-up |
| |
|---|---|---|---|---|---|---|
| Leptin (mg/dL) | 29.0 ± 4.4 | 32.6 ± 4.1 | n.s. | 3.6 (−12.1 to 20.6) | 31.2 ± 4.2 | n.s. |
| Adiponectin ( | 9.54 ± 1.33 | 7.90 ± 1.08 | n.s. | −1.6 (−8.5 to 4.3) | 7.66 ± 1.06 | n.s. |
| Glucose (mg/dL) | 100.9 ± 1.9 | 105.7 ± 3.3 | 0.07 | 4.8 (−5.6 to 20.5) | 105.7 ± 2.7 | n.s. |
| Insulin (mU/L) | 10.6 ± 1.7 | 12.2 ± 2.1 | n.s. | 1.7 (−2.3 to 15.2) | 11.4 ± 1.6 | n.s. |
| HOMA-IR | 2.61 ± 1.27 | 3.16 ± 0.54 | n.s | 0.6 (−0.5 to 4.1) | 3.00 ± 0.47 | n.s. |
| CRP ( | 4.45 ± 1.39 | 5.91 ± 1.85 | n.s | 1.5 (−1.2 to 6.5) | 6.10 ± 1.73 | n.s |
| TNF- | 33.24 ± 3.10 | 33.69 ± 2.69 | n.s | 0.4 (−10.7 to 20.4) | 37.58 ± 2.03 | n.s |
Data are expressed as mean ± SEM; n.s., not significant.
P: ANOVA.
Δa: differences from after to before COJ (mean values and their 95% confidence intervals).
Figure 2Pattern of change in CRP (μg/mL) and TNF-α (pg/mL) by BMI levels.
Figure 3Pattern of change in leptin (mg/dL) and adiponectin (μg/dL) by BMI levels.